Therapeutic uses of empaglifozina.
- 专利权人:
- BOEHRINGER INGELHEIM INTERNATIONAL GmbH
- 发明人:
- BROEDL ULI,VON EYNATTEN MAXIMILIAN,WOERLE HANS-JUERGEN,MACHA SREERAJ
- 申请号：
- CL2015002940
- 公开号：
- CL2015002940A1
- 申请日:
- 2015.10.02
- 申请国别(地区):
- CL
- 年份:
- 2016
- 代理人:
- 摘要：
- Use of empaglifozina to treat diabetes, Type 1 or type 2 diabetes mellitus, or improve glycaemic control in patients with moderate renal failure or chronic kidney disease (CKD) In Phase 3； Pharmaceutical composition comprising empaglifozina.USO DE UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE EMPAGLIFLOZINA PARA PREPARAR UN MEDICAMENTO ÚTIL PARA TRATAR LA DIABETES MELLITUS TIPO 2.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- CURCUMIN COMBINATION WITH ANTI-TYPE 2 DIABETIC DRUGS FOR PREVENTION AND TREATMENT OF DISEASE SEQUELAE, DRUG-RELATED ADVERSE REACTIONS, AND IMPROVED GLYCEMIC CONTROL
- CURCUMIN COMBINATION WITH ANTI-TYPE 2 DIABETIC DRUGS FOR PREVENTION AND TREATMENT OF DISEASE SEQUELAE, DRUG-RELATED ADVERSE REACTIONS, AND IMPROVED GLYCEMIC CONTROL
- CURCUMIN COMBINATION WITH ANTI-TYPE 2 DIABETIC DRUGS FOR PREVENTION AND TREATMENT OF DISEASE SEQUELAE, DRUG-RELATED ADVERSE REACTIONS, AND IMPROVED GLYCEMIC CONTROL
- Pharmaceutical composition comprising a release delayed release oral form that has a Core comprising a Biguanide compound and an Enteric coating, and methods to reduce adverse events of the compounds to treat Metabolic Disorders, reduce the onset of Diabetes Teas and induce Weight Loss.
